(来源:新康界)转自:新康界1月14日晚,药明生物发布公告,宣布一项收购要约,旗下子公司药明合联将收购东曜药业。在ADC领域商业化进程加速、产能成为关键稀缺资源的背景下,这步棋相当于跳过了自建厂房通常所需的3—5年周期,以资本换时间,迅速将图纸上的产能转化为手中的实际交付能力。这不仅能够在当前产能竞争中占据主动,更有望凭借其全方位布局,主导未来生物偶联药CDMO行业格局。溢价超100%文件显示,...
Source Link(来源:新康界)转自:新康界1月14日晚,药明生物发布公告,宣布一项收购要约,旗下子公司药明合联将收购东曜药业。在ADC领域商业化进程加速、产能成为关键稀缺资源的背景下,这步棋相当于跳过了自建厂房通常所需的3—5年周期,以资本换时间,迅速将图纸上的产能转化为手中的实际交付能力。这不仅能够在当前产能竞争中占据主动,更有望凭借其全方位布局,主导未来生物偶联药CDMO行业格局。溢价超100%文件显示,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.